Investments in German Pharma Continue to Surge
Germany is considered as one of the most advanced pharma markets in the world. The country is now on the radar of global pharma majors and most of these are looking to expand their operations in the country. The country’s strong research and development infrastructure has also attracted lot of investors to the country. This has boosted the growth of German pharma market. As per our new research on the sector called “German Pharma Sector Analysis”, the pharma market in Germany is projected to grow at a CAGR of around 5% during 2010-2012.
Generics dominate the German pharmaceutical market at present. We have found that Germany pharma is one of most generics-friendly market in the world and more than two-thirds of total prescriptions in the country are of generic drugs. It has been seen that branded drugs loose almost their complete share in the market to the generics version just after few months of patent expiration. In this regard, our report provides a complete analysis of the German generic drugs industry.
Apart from this, we have studied all the company-level trends prevailing in the industry and our research report provides complete analysis of these existing trends. We believe that regulatory environment plays an important role in the development of pharma market and thus, our research report provides complete detail of the pharma regulatory environment in the country. The report also provides information on various government steps and initiatives that have been taken to improve the growth of the pharma market.
“German Pharma Sector Analysis” is an outcome of our extensive research and in-depth analysis. The report provides various industry forecasts, which are completely based on our various in-house statistical models. Moreover, it also provides information on various key players highlighting their strengths and weaknesses. Thus, the report presents a clear and unbiased picture of the German pharma market to clients and helps them in making smart and intelligent investment decisions.